Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

ARGX

Argen X SE ADR

May 31 • 04:00PM ET

371.02

Dollar change +8.86
Percentage change 2.45	%

Healthcare • Biotechnology • Netherlands • NASD

Stock Detail • Compare Perf. • Financials • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-5.17	Insider Own	0.71%	Shs Outstand	59.19M	Perf Week	2.77%
Market Cap	22.05B	Forward P/E	126.59	EPS next Y	2.93	Insider Trans	0.00%	Shs Float	59.01M	Perf Month	-3.21%
Income	-295.51M	PEG	-	EPS next Q	-0.93	Inst Own	56.75%	Short Float	2.26%	Perf Quarter	-5.71%
Sales	1.23B	P/S	17.95	EPS this Y	47.59%	Inst Trans	-7.18%	Short Ratio	4.89	Perf Half Y	-14.89%
Book/sh	69.22	P/B	5.36	EPS next Y	208.38%	ROA	-7.70%	Short Interest	1.34M	Perf Year	-4.55%
Cash/sh	53.51	P/C	6.93	EPS next 5Y	-	ROE	-8.55%	52W Range	327.73 - 550.76	Perf YTD	-2.47%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-17.05%	ROI	-7.18%	52W High	-32.63%	Beta	0.65
Dividend TTM	-	Quick Ratio	9.01	Sales past 5Y	287.78%	Gross Margin	81.59%	52W Low	13.21%	ATR (14)	12.49
Dividend Ex-Date	-	Current Ratio	9.75	EPS Y/Y TTM	60.46%	Oper. Margin	-37.75%	RSI (14)	49.56	Volatility	3.29% 3.29%
Employees	1148	Debt/Eq	0.00	Sales Y/Y TTM	198.89%	Profit Margin	-24.06%	Recom	1.62	Target Price	465.44
Option/Short	Yes / Yes	LT Debt/Eq	0.00	EPS Q/Q	10.02%	Payout	-	Rel Volume	1.21	Prev Close	362.16
Sales Surprise	2.02%	EPS Surprise	-34.80%	Sales Q/Q	82.26%	Earnings	May 09 BMO	Avg Volume	273.24K	Price	371.02
SMA20	-0.65%	SMA50	-1.94%	SMA200	-13.61%	Trades		Volume	331,705	Change	2.45%

Date	Action	Analyst	Rating Change	Price Target Change
Feb-15-24	Initiated	Wolfe Research	Peer Perform
Dec-20-23	Downgrade	William Blair	Outperform → Mkt Perform
Dec-20-23	Downgrade	Deutsche Bank	Buy → Hold
Jul-31-23	Initiated	Scotiabank	Sector Perform	$516
Jul-24-23	Downgrade	UBS	Buy → Neutral	$480 → $570
Jul-17-23	Resumed	Evercore ISI	Outperform	$436
Jun-15-23	Initiated	Societe Generale	Sell
May-31-23	Initiated	UBS	Buy	$480
Apr-25-23	Initiated	Citigroup	Buy	$450
Mar-14-23	Upgrade	Robert W. Baird	Neutral → Outperform	$460
Dec-07-22	Initiated	William Blair	Outperform
Oct-12-22	Initiated	Oppenheimer	Perform
Jul-29-22	Downgrade	Robert W. Baird	Outperform → Neutral	$374 → $460
Jun-28-22	Resumed	Stifel	Buy	$460
May-03-22	Upgrade	Morgan Stanley	Equal-Weight → Overweight	$375
Dec-08-21	Initiated	Wells Fargo	Overweight	$390
Nov-29-21	Upgrade	Piper Sandler	Neutral → Overweight	$250 → $354
Oct-29-21	Upgrade	Guggenheim	Neutral → Buy	$330
Oct-28-21	Upgrade	Raymond James	Outperform → Strong Buy	$390
Oct-07-21	Initiated	Jefferies	Buy	$362

Show Previous Ratings

May-30-24 04:02PM	After Biohaven Kerfuffle, Immunovant Dives On A Surprise Delay (Investor's Business Daily)
May-29-24 04:06PM	Biohaven Tumbles After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump (Investor's Business Daily)
10:17AM	Biohaven Crashes After Protein-Degrading Drug Misses Expectations; Immunovant, Argenx Jump (Investor's Business Daily)
May-14-24 06:43PM	Analyst Report: argenx SE (Morningstar Research)
May-13-24 10:30AM	JPMorgan Cuts Price Target on Argenx to $500 From $560, Maintains Overweight Rating (MT Newswires)
04:25PM	Loading…
May-10-24 04:25PM	argenx SE (NASDAQ:ARGX) Q1 2024 Earnings Call Transcript (Insider Monkey)
May-09-24 12:28PM	Analyst Report: argenx SE (Morningstar Research)
06:52AM	ARGX Stock Earnings: argenx Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
01:00AM	argenx Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-08-24 10:56AM	Is a Surprise Coming for argenx (ARGX) This Earnings Season? (Zacks)
May-07-24 05:30PM	argenx announces results of Annual General Meeting of Shareholders (GlobeNewswire)
01:00AM	argenx to Present at BofA Securities 2024 Health Care Conference (GlobeNewswire)
May-02-24 06:42PM	Analyst Report: argenx SE (Morningstar Research)
01:00AM	argenx to Report First Quarter 2024 Financial Results and Business Update on May 9, 2024 (GlobeNewswire)
Apr-16-24 01:00AM	argenx Data Highlight Evidence that VYVGART and VYVGART Hytrulo Drive Transformative Outcomes for Patients with Debilitating Autoimmune Disease (GlobeNewswire)
04:42AM	Loading…
Mar-29-24 04:42AM	Here's Why argenx SE (ARGX) Pulled Back 23% in Q4 (Insider Monkey)
Mar-27-24 02:00AM	argenx Advances Clinical Development of Efgartigimod in Primary Sjogren's Disease (GlobeNewswire)
Mar-26-24 04:00PM	argenx Announces Annual General Meeting of Shareholders on May 7, 2024 (GlobeNewswire)
02:00AM	argenx Announces Approval of VYVGART (efgartigimod alfa) in Japan for Adults with Primary Immune Thrombocytopenia (GlobeNewswire)
Mar-22-24 10:28AM	Why Argenx's (ARGX) Stock Price Moved Up 11% on Thursday (Zacks)
07:47AM	Argenx (ARGX) Moves 11.2% Higher: Will This Strength Last? (Zacks)
Mar-21-24 04:45PM	Argenx, Immunovant Soar As Tourmaline Plummets On A Rival's Lackluster Test Results (Investor's Business Daily) +11.19%
Mar-20-24 06:38PM	Analyst Report: argenx SE (Morningstar Research)
Mar-19-24 07:16AM	Reasons to Invest in argenx (ARGX) (Insider Monkey)
Mar-17-24 08:49AM	5 Biggest Biotechnology Companies in the World (Insider Monkey)
Mar-07-24 04:01PM	argenx Delivers on Promise to Transform Patient Expectations in Autoimmunity at American Academy of Neurology 2024 Annual Meeting (GlobeNewswire)
08:14AM	Ascendis Pharma A/S (ASND) Faced R&D Setbacks in Q4 (Insider Monkey)
07:28AM	Should You be Confident in Your Investment in argenx SE (ARGX)? (Insider Monkey)
Mar-01-24 10:12AM	argenx SE (NASDAQ:ARGX) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-29-24 10:16PM	Analyst Report: argenx SE (Morningstar Research)
01:00AM	Loading…
01:00AM	argenx Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update (GlobeNewswire)
Feb-28-24 08:38AM	Is a Surprise Coming for argenx (ARGX) This Earnings Season? (Zacks)
Feb-26-24 01:00AM	argenx to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-22-24 08:00AM	Argenx Is Tracking Well Above the Industry (GuruFocus.com)
01:00AM	argenx to Report Full Year 2023 Financial Results and Fourth Quarter Business Update on February 29, 2024 (GlobeNewswire)
Feb-21-24 10:08PM	3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition (InvestorPlace)
Feb-20-24 01:00AM	argenx Announces FDA Acceptance of Supplemental Biologics License Application with Priority Review for VYVGART Hytrulo in Chronic Inflammatory Demyelinating Polyneuropathy (GlobeNewswire)
Jan-22-24 05:35AM	Argenx SE (ARGX) Declined on Failed Clinical Trials (Insider Monkey)
Jan-18-24 01:00AM	argenx Announces Approval of VYVDURA (efgartigimod alfa and hyaluronidase-qvfc) Injection for Subcutaneous Use in Japan for Generalized Myasthenia Gravis (GlobeNewswire)
Jan-12-24 08:30AM	How Argenx (ARGX) Stock Stands Out in a Strong Industry (Zacks)
Jan-08-24 01:00AM	argenx Highlights 2024 Strategic Priorities (GlobeNewswire)
Jan-04-24 06:44PM	Analyst Report: argenx SE (Morningstar Research)
Jan-02-24 01:00AM	argenx to Present at 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-23 05:05AM	UPDATE 2-European shares end slightly higher ahead of Christmas holiday (Reuters) +5.30%
Dec-21-23 04:09PM	Immunovant Scores Much-Needed Win Following Argenx-Led Sell-off (Investor's Business Daily)
09:50AM	argenx (ARGX) Tanks on Top-Line Data From Pemphigus Study (Zacks)
Dec-20-23 04:33PM	Stock Market Does Sharp About-Face; Dow Breaks Win Streak (Investor's Business Daily) -25.12%
04:02PM	Argenx Crashes 25% As The Setbacks Mount For Its Hallmark Drug, Vyvgart (Investor's Business Daily)
03:20PM	Stock Market Reverses Sharply Lower; FedEx Stock Worst In S&P 500 (Investor's Business Daily)
12:15PM	Analyst Report: argenx SE (Morningstar Research)
07:26AM	Argenx Dives On Autoimmune Therapy Failure (Investor's Business Daily)
06:30AM	Argenx autoimmune drug study fails in blow to expansion hopes (BioPharma Dive)
01:00AM	argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus (GlobeNewswire)
Dec-18-23 03:17AM	argenx SE's (ARGX) Share Price Increased By 28% Due to Several Factors (Insider Monkey)
Dec-12-23 03:04PM	30 Largest Pharmaceutical Companies in the World (Insider Monkey)
Dec-08-23 05:19AM	Why is Argenx (ARGX) a Suitable Investment Option? (Insider Monkey)
Dec-03-23 05:25AM	12 Stocks Billionaire Steve Cohen Just Bought and Sold (Insider Monkey)
Dec-01-23 06:55AM	Several Catalysts Pushed argenx SE (ARGX) in Q3 (Insider Monkey)
Nov-28-23 06:59PM	Analyst Report: argenx SE (Morningstar Research) -10.17%
04:04PM	Argenx Stock Crashes On An Unexpected Failure For Its Biggest Drug (Investor's Business Daily)
12:06PM	Carlyle Group, Seadrill rise; PG&E, Argenx fall, Tuesday, 11/28/2023 (Associated Press Finance)
08:51AM	These 2 Stocks Are Falling in a Fading Rally (Motley Fool)
05:17AM	UPDATE 2-November rally in European stocks stalls after comments from ECB officials (Reuters)
01:00AM	argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia (GlobeNewswire)
Nov-16-23 07:40AM	argenx Announces European Commission Approval of Subcutaneous VYVGART (efgartigimod alfa) for Generalized Myasthenia Gravis (GlobeNewswire)
Nov-07-23 11:22AM	Q3 2023 Halozyme Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
09:04AM	Here's Why You Should Consider Investing in Argenx SE (ARGX) (Insider Monkey)
Nov-06-23 01:16PM	Tech Titans Rising: 7 Underrated Stocks Set for Explosive Growth (InvestorPlace)
Nov-05-23 05:54PM	Analyst Report: argenx SE (Morningstar Research)
Nov-01-23 10:57PM	Analyst Report: argenx SE (Morningstar Research) +5.37%
10:15AM	argenx SE (NASDAQ:ARGX) Q3 2023 Earnings Call Transcript (Insider Monkey)
02:00AM	argenx to Present at Upcoming Investor Conferences (GlobeNewswire)
02:00AM	argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions (GlobeNewswire)
Oct-31-23 05:05PM	Analyst Report: argenx SE (Morningstar Research)
04:05PM	Argenx Posts Strong Results For 'Seventh Straight Quarter Of Outperformance' (Investor's Business Daily)
09:14AM	Argenx Comes Up With Big Sales Beat, Narrower-Than-Expected Losses (Investor's Business Daily)
02:00AM	argenx Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire)
Oct-24-23 01:00AM	argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023 (GlobeNewswire)
Oct-20-23 03:24AM	argenx SE (ARGX) Rose on Reporting Positive Data (Insider Monkey)
Oct-05-23 08:13AM	IQVIA (IQV) and argenx Partner to Advance Autoimmune Care (Zacks)
Sep-27-23 04:09PM	Biohaven, Yet Another Rival To Argenx In Autoimmune Drugs, Just Rocketed 33% (Investor's Business Daily)
04:06PM	Immunovant Parlays Its Shot At Rivaling Argenx Into A $300 Million Offering (Investor's Business Daily)
12:25PM	Biohaven, Yet Another Argenx Rival In Autoimmune Drugs, Just Rocketed 29% (Investor's Business Daily)
Sep-26-23 04:13PM	Immunovant Doubles And Slugs Argenx As Autoimmune Disease Battle Heats Up (Investor's Business Daily)
10:01AM	Immunovant Soars 73% And Slugs Argenx As Autoimmune Disease Battle Heats Up (Investor's Business Daily)
Sep-21-23 01:00AM	argenx Announces VYVGART (efgartigimod alfa) Authorized for Sale by Health Canada for Generalized Myasthenia Gravis (GlobeNewswire)
Sep-17-23 09:50AM	New S&P 500 Entrant Airbnb And DKNG Lead 5 Stocks Near Buy Points (Investor's Business Daily)
Sep-16-23 09:00AM	This New S&P 500 Entrant Leads 5 Stocks Near Buy Points (Investor's Business Daily)
09:00AM	DKNG Stock And New S&P 500 Entrant Airbnb Lead 5 Stocks Near Buy Points (Investor's Business Daily)
Sep-15-23 04:27PM	How IBD Stock Of The Day Argenx, A Top-Notch Biotech, Is Dominating With One Drug (Investor's Business Daily)
01:00AM	argenx Announces Positive CHMP Opinion for Subcutaneous Efgartigimod for Generalized Myasthenia Gravis (GlobeNewswire)
Aug-30-23 01:00AM	argenx to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-21-23 01:44AM	Should You Consider Adding argenx SE (ARGX) to Your Portfolio? (Insider Monkey)
Aug-19-23 11:02AM	Top AI Stock ANET Leads 5 Stocks Near Buy Points In Tough Market (Investor's Business Daily)
Aug-09-23 12:19PM	Halozyme (HALO) Q2 Earnings & Revenues Beat, 2023 View Raised (Zacks)
Jul-31-23 10:00AM	Is Argenx Stock a Buy Now? (Motley Fool)
09:51AM	Adobe upgraded, Salesforce downgraded: Wall Street's top analyst calls (The Fly)
Jul-28-23 10:59AM	Analyst Report: argenx SE (Morningstar Research)
Jul-27-23 04:12PM	Argenx Beats Earnings Expectations As Sales Of 'Megabuster' Drug Grow 260% (Investor's Business Daily)
08:29AM	Argenx Beats Q2 Earnings Expectations As Sales Of 'Megabuster' Drug Grow 260% (Investor's Business Daily)

argenx SE is a global immunology company, which engages in improving the lives of people suffering from severe autoimmune diseases. It operates through the following geographical segments: United States, Japan, EMEA, and China. The company was founded by Hans J. W. de Haard, Torsten Dreier, and Tim van Hauwermeiren in 2008 and is headquartered in Amsterdam, the Netherlands.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ARGX

Argen X SE ADR

Upgrade your FINVIZ experience